Your basket is currently empty!
Take The Kidney Cancer UK Patient Survey 2025
Welcome to the 12th year of the Kidney Cancer UK Patient Survey, the only survey dedicated solely to UK ...
Author Archive
Malcolm Packer
Malcolm is Chief Executive Officer at Kidney Cancer UK and Kidney Cancer Scotland and has worked with the charity in various capacities for over 15 years.
NICE launched its consultation on new draft kidney cancer clinical guideline
The National Institute for Health and Care Excellence (NICE) first guideline on kidney cancer recommends better ...
National Kidney Cancer Audit report pinpoints areas for improvement in England
The National Kidney Cancer Audit (NKCA) published its second annual State of the Nation report on Thursday 11th ...
Remembering James Whale MBE, 1951 – 2025
It is with deep sadness that we share the news of the passing of our friend, founder, and Lifetime President of ...
NHS 10-year plan Statement
The Government’s new ten-year plan for the NHS, published on 3rd July 2025, places emphasis on providing treatment ...
Dr Sabrina H Rossi presents findings from 10-Year Survey
Kidney Cancer UK, working with researchers from the University of Cambridge, are putting patients at the centre of ...
GIRFT (Getting It Right First Time)
GIRFT (Getting It Right First Time) programme is a national NHS England programme designed to improve the ...
MHRA authorises cancer treatment variation with an administration time of 3–5 minutes
On 30 April 2025, the Medicines and Healthcare Products Regulatory Agency (MHRA) approved a new under-the-skin ...
AI predicts kidney cancer therapy response
An artificial intelligence (AI)-based model developed by UT Southwestern Medical Centre researchers can accurately ...
Our Brand New Shop and Products
Visit our brand new shop with lots of fabulous new items.
We have lots of new Kidney Cancer UK branded products ...
*New* Audiobook – Diagnosis
As part of Kidney Cancer Awareness Week, we are delighted to launch the first audiobook from our Understanding ...
Five-year results see Exelixis’ RCC therapy extending overall survival
Studied in combination with Opdivo, Cabometyx saw RCC patients surviving 11 months longer than Sunitinib patients ...
No results found.